A Multi-center, Randomized, Double-blind, Placebo-controlled, Four-arm Parallel-group Trial to Investigate the Efficacy and Safety of Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome

Trial Profile

A Multi-center, Randomized, Double-blind, Placebo-controlled, Four-arm Parallel-group Trial to Investigate the Efficacy and Safety of Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Oct 2014

At a glance

  • Drugs Rotigotine (Primary)
  • Indications Restless legs syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors UCB Pharma Inc
  • Most Recent Events

    • 28 Jul 2010 Results have been published in the journal, Movement Disorders, according to a UCB media release. Results were discussed further within the media release.
    • 18 Jun 2010 Quality of life outcomes were presented at the 14th International Congress of Parkinson's Disease and Movement Disorders, according to a UCB media release.
    • 17 Jun 2010 Results were reported at the 14th International Congress of Parkinson's Disease and Movement Disorders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top